COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03288324
Recruitment Status : Recruiting
First Posted : September 20, 2017
Last Update Posted : July 15, 2020
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati

Brief Summary:
This 76-week, 3-part Phase 1b/2 study is intended to evaluate the pharmacological properties (pharmacokinetics and pharmacodynamics), safety, tolerability and preliminary effectiveness of TOFA administrated to young adults (18-45 years) with moderately to severely active SLE-CL. Subjects will be studied at the Cincinnati Children's Hospital Medical Center (CCHMC) and in Cleveland at MetroHealth Medical Center.

Condition or disease Intervention/treatment Phase
Cutaneous Lupus Systemic Lupus Erythematosus Drug: Tofacitinib Phase 1 Phase 2

Detailed Description:

Cohort 1 (n=10, weight > 40kg and age > 18 years and ≤ 45 years ) will undergo intense PK-sampling to determine exposures following TOFA dosed at 5 mg BID. TOFA dose escalation will not be considered for inadequate response of SLE-CL.

Cohort 2 (n=10, weight > 40kg and age > 18 years and ≤ 45 years) will be treated with the same dose as Cohort 1. No PK sampling will occur for Cohort 2. Enrollment of Cohort 2 will only start once Cohort 1 has completed 8 weeks of TOFA and results of PK analyses from Cohort 1 are available.

  • Part A (up to week 8) requires stable background medications;
  • Part B (up to week 24) allows for tapering of corticosteroids (CS) in the setting of significant clinical improvement of SLE-CL as defined by a decrease in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score by >50% from baseline , and
  • Part C (until week 76) permits tapering of other background medications in subjects with clinical remission of SLE-CL (CLASI activity score=0). TOFA dosing is kept stable during Part C.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus
Actual Study Start Date : August 23, 2017
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Tofacitinib Arm
open-label study
Drug: Tofacitinib
Tofacitinib 5 mg twice daily
Other Name: Xeljanz

Primary Outcome Measures :
  1. Oral Clearance (CL/F) (Cohort 1 only) [ Time Frame: Day 5 ]
    Apparent total clearance of the drug from plasma after oral administration

Secondary Outcome Measures :
  1. Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score [ Time Frame: weeks 4, 8 and 24 compared to baseline. ]
    Proportion of subjects who achieve a skin response per the validated CLASI

  2. AUCt (Cohort 1 only) [ Time Frame: Day 5 ]
    Area under the plasma concentration-time curve from time zero to time t

  3. Cmax (Cohort 1 only) [ Time Frame: Day 5 ]
    Maximum (or peak) plasma concentration of Tofacitinib

  4. tmax (Cohort 1 only) [ Time Frame: Day 5 ]
    Time to reach maximum (peak) plasma concentration following administration of Tofacitinib

  5. Vz/F (Cohort 1 only) [ Time Frame: Day 5 ]
    Apparent volume of distribution during terminal phase after non-intravenous administration

  6. half-life of Tofacitinib (Cohort 1 only) [ Time Frame: Day 5 ]
    half-life of Tofacitinib

  7. Safety of Tofacitinib: Nature, severity, and frequency of adverse events (Cohorts 1 and 2) [ Time Frame: 76 weeks ]
    Rate and severity of adverse events and lab abnormalities

Other Outcome Measures:
  1. Steroid dose comparison [ Time Frame: 76 weeks ]
    Assess steroid sparing properties of Tofacitinib by comparing doses to baseline and rate of steroid discontinuation

  2. Change in SLE Disease Activity Index (SLEDAI) score [ Time Frame: 76 weeks ]
    Measure Tofacitinib impact on disease activity

  3. Change in British Isles Lupus Activity Group (BILAG) score [ Time Frame: 76 weeks ]
    Measure Tofacitinib impact on disease activity

  4. Change in SKINDEX score [ Time Frame: Baseline, week 24 and week 76 ]
    Quality-of-life measure for patients with skin disease

  5. Change in patients global assessment score [ Time Frame: Baseline, week 24 and week 76 ]
    Quality-of-life measure for patients

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female > 18 years of age and < 45 years of age and > 40 kg body weight.
  2. Fulfilled at least 4 out of the 11 Classification Criteria for SLE by the time of screening.
  3. Willing to give written informed consent, must fully understand the requirements of the trial, and must be willing to comply with all trial visits and assessments.
  4. CLASI activity score of 8 or higher at screening and baseline despite standard of care therapy.
  5. Stable dose of prednisone of ≤ 20 mg/day within 2 weeks of enrollment.
  6. Female subjects of childbearing potential must use a highly effective method of contraception to prevent pregnancy (abstinence is considered highly effective) and must agree to continue to practice adequate contraception for the duration of their participation in the trial and for 28 days after their last dose of TOFA.
  7. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at Trial Day 1 before dosing.
  8. For subjects receiving leflunomide treatment, total daily dose does not exceed 20 mg.
  9. A negative QuantiFERON-TB Gold In-Tube test performed within the 3 months prior to screening, or within the screening period prior to baseline. A negative PPD test can be substituted for the QuantiFERON-TB.
  10. Subjects either have protective varicella titers or evidence of having been vaccinated against varicella.

Exclusion Criteria:

  1. Mild SLE-CL defined as a CLASI activity score of 7 or lower at screening and baseline.
  2. Increase in CS dosing within 2 weeks prior to Trial Day 1, or expected to require an increase in CS dosing during the first 4 weeks of the study.
  3. Use of i.v. corticosteroids within 4 weeks prior to Trial Day 1.
  4. Increase in dosing of methotrexate, leflunomide, within 4 weeks before Trial Day 1 or expected to require an increase during the first 8-weeks of the study.
  5. Increase in dosing of hydroxychloroquine, or chloroquine within 4 weeks before Trial Day 1 or expected to require an increase during the first 8-weeks of the study.
  6. Rituximab within 1 year of Trial Day 1.
  7. Increase in dosing of any medication or herbal treatment considered to have immunosuppressive properties with 4 weeks before Trial Day 1.
  8. Prior treatment with or known intolerability of TOFA.
  9. Use of cyclophosphamide (i.v. or oral), cyclosporine, or tacrolimus within 12 weeks prior to Trial Day 1.
  10. Treatment with other investigational agents within the last 6 months or 5 half-lives, or as per washout requirement from the previous protocol, whichever is longer.
  11. Estimated glomerular filtration rate less than or equal to 60 mL/min /1.73 m2.
  12. Known positive Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), or Hepatitis B surface antigen (HBsAg) serology.
  13. Any condition, including findings in the laboratory tests, medical history, or other screening assessments, that, in the opinion of the Investigator, constitutes an inappropriate risk or a contraindication for participation in the trial or that could interfere with the trial's objectives, conduct, or evaluation.
  14. Active central nervous system SLE deemed to be severe or progressive and/or associated with significant cognitive impairment leading to inability to provide informed consent and/or comply with the protocol.
  15. Significant renal disease due to a reason(s) other than Lupus Nephritis (e.g. diabetes mellitus, renovascular disease, or antiphospholipid syndrome).
  16. Severely active Lupus Nephritis defined as a renal BILAG A score.
  17. History of dialysis within 3 months prior to Trial Day 1 or expected to need during the trial.
  18. History of or planned renal or other organ transplantation.
  19. Known active clinically significant viral, bacterial or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 8 weeks of screening, or completion of oral anti-infectives within 2 weeks of Trial Day 1.
  20. Breastfeeding or currently pregnant.
  21. Legal incapacity or limited legal capacity to provide informed consent or assent.
  22. Blood dyscrasias, including:

    • Hgb <10 g/dL or Hct <33%.
    • WBC <3.0 x 109/L.
    • Neutrophil count <1.2 x 109/L.
    • Platelet count <100 x 109/L.
    • Lymphocyte count of <0.5 x 109/L.
  23. AST or ALT > 1.5 times the upper limit of normal or any other clinically significant laboratory abnormality.
  24. History of any other rheumatic autoimmune disease.
  25. Infections:

    • Latent or active TB or any history of previous TB.
    • Chronic infections.
    • Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 6 months prior to the first dose of study drug.
    • Any treated infections within 2 weeks.
    • History of recurrent (more than one episode) herpes zoster or disseminated (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.
    • History or current symptoms suggestive of any lymphoproliferative disorder, including Cytomegaly Virus (CMV) or Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease.
  26. Subjects taking potent and moderate cytochrome P450 3A4 (CYP3A4) inhibitors (see Appendix 2).
  27. Subjects taking potent and moderate CYP3A4 inducers (see Appendix 2).
  28. Subjects who have been vaccinated with live or attenuated vaccines within the 6 weeks prior to the first dose of study medication. All subjects should be up-to-date with respect to standard of care vaccinations (as defined by their country health ministry) as permitted by past immunosuppressive therapy for SLE.
  29. Subjects with a malignancy or with a history of malignancy with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
  30. Subjects with a history or current diagnosis of diverticulitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03288324

Layout table for location contacts
Contact: Angela CRC 513-803-2118

Layout table for location information
United States, Ohio
Cincinnati Childrens Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Angela SR CRC    513-803-2118   
MetroHealth Medical Center Recruiting
Cleveland, Ohio, United States, 44109
Contact: Nora Singer, MD   
Contact: Darerian Schueller    216-778-2380   
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Layout table for investigator information
Principal Investigator: Hermine Brunner, MD Cincinnati Childrens Hospital Medical Center
Layout table for additonal information
Responsible Party: Children's Hospital Medical Center, Cincinnati Identifier: NCT03288324    
Other Study ID Numbers: WI211648
First Posted: September 20, 2017    Key Record Dates
Last Update Posted: July 15, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action